Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment?

It is unknown whether home blood pressure (BP) variability reduction is associated with target organ damage (TOD) protection independently of home mean BP reduction. We enrolled 310 hypertensive patients whose systolic BP (SBP) at home was over 135 mm Hg. The subjects measured their BP in the mornin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hypertension research 2012-08, Vol.35 (8), p.862-866
Hauptverfasser:	Hoshide, Satoshi, Yano, Yuichiro, Shimizu, Motohiro, Eguchi, Kazuo, Ishikawa, Joji, Kario, Kazuomi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Albuminuria - metabolism Angiotensin II Type 1 Receptor Blockers - therapeutic use Antihypertensive Agents - therapeutic use Benzimidazoles - therapeutic use Blood Pressure - drug effects Blood Pressure Monitoring, Ambulatory Creatinine - urine Diuretics - therapeutic use Female Humans Hypertension - drug therapy Hypertension - physiopathology Linear Models Male Middle Aged Nephelometry and Turbidimetry Tetrazoles - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	It is unknown whether home blood pressure (BP) variability reduction is associated with target organ damage (TOD) protection independently of home mean BP reduction. We enrolled 310 hypertensive patients whose systolic BP (SBP) at home was over 135 mm Hg. The subjects measured their BP in the morning and evening for 7 days. In addition, we measured urinary albumin excretion (UAE) as a marker of TOD before and after 6 months of candesartan treatment (+thiazidediuretics). At baseline, UAE was associated with average home SBP (r=0.24, P
ISSN:	0916-9636 1348-4214
DOI:	10.1038/hr.2012.46